Citation: Journal of Pain & Symptom Management. 2018 Dec 19.Journal: Journal of pain and symptom management.Published: ; 2018ISSN: 0885-3924.Full author list: McPherson ML; Walker KA; Davis MP; Bruera E; Reddy A; Paice J; Malotte K; Lockman DK; Wellman C; Salpeter S; Bemben NM; Ray JB; Lapointe BJ; Chou R.UI/PMID: 30578934.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Health Research InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1016/j.jpainsymman.2018.12.001 (Click here)Abbreviated citation: J Pain Symptom Manage. 2018 Dec 19.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007.Abstract: Methadone has several unique characteristics that make it an attractive option for pain relief in serious illness, but the safety of methadone has been called into question after reports of a disproportionate increase in opioid-induced deaths in recent years. The American Pain Society (APS), College on Problems of Drug Dependence, and the Heart Rhythm Society collaborated to issue guidelines on best practices to maximize methadone safety and efficacy, but guidelines for the end-of-life scenario have not yet been developed. A panel of 15 interprofessional hospice and palliative care experts from the US and Canada convened in February 2015 to evaluate the APS methadone recommendations for applicability in the hospice and palliative care setting. The goal was to develop guidelines for safe and effective management of methadone therapy in hospice and palliative care. This article represents the consensus opinion of the hospice and palliative care experts for methadone use at end of life, including guidance on appropriate candidates for methadone, detail in dosing, titration, and monitoring of patients' response to methadone therapy.Abstract: Copyright (c) 2018 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.